Posts by: Santiago Gisler

Santiago Gisler

May 21, 2019June 5, 2019

EMD Serono Launches MS-LINK Research Network to Improve Patient Care

News

EMD Serono, the biopharmaceutical division of Merck KGaA in the U.S. and Canada, announced the launch of the company’s Multiple Sclerosis Leadership and Innovation Network (MS-LINK), an interdisciplinary research ... Read more

May 20, 2019May 20, 2019

Study Testing Pear-006 Software Application for Treating Depression Symptoms

News

Pear Therapeutics, in collaboration with Novartis, has launched a study evaluating the clinical use of Pear-006, its software-based prescription digital therapeutics (PDT) product for treating depression symptoms in people with ... Read more

April 30, 2019April 30, 2019

Retrospective Study Analyzes Physical, Mental Differences Between Children with MS and ADS

News

Retrospective comparison between children with multiple sclerosis (MS) and those with related acute demyelinating syndromes (ADS) highlights the implications of fatigue, depression, and quality of life in these patients. ... Read more

April 29, 2019April 29, 2019

Relapsing MS Patients Highly Satisfied with Aubagio’s Efficacy and Ease of Use, Global Clinical Study Finds

Aubagio, News

High levels of satisfaction with the efficacy and convenience of Aubagio (teriflunomide), an oral treatment for relapsing multiple sclerosis (MS), were reported by patients across the U.S. and 13 other countries, ... Read more

April 17, 2019April 17, 2019

First Large-scale Clinical Genomic Research Study Aims to Improve Personalized MS Treatment

News

A collaboration between DNAnexus, the Sutter Health network, and the University Pittsburgh Medical Center (UPMC) aims to improve personalized medicine in multiple sclerosis (MS) through the first large-scale clinical genomic ... Read more

March 26, 2019March 26, 2019

AscellaHealth Highlights Support Program for MS Patients in Recognition of MS Awareness Month

News

In recognition of Multiple Sclerosis Awareness Month, AscellaHealth, a national pharmacy benefit management company, is calling attention to its clinical and educational program designed to assist individuals with multiple sclerosis ... Read more

March 21, 2019March 21, 2019

Schwann Cells Stop Blood-clotting Protein Thrombin from Damaging Nerves, Study Finds

News

Schwann cells surrounding neurons protect the degeneration of nerves by blocking thrombin, a blood-clotting protein that can also damage nerves, according to a new study. These findings may aid in ... Read more

March 13, 2019March 15, 2019

Phase 2 Trial Will Assess Autologous Mesenchymal Stem Cell Therapy to Treat Progressive Forms of MS

News

The National Multiple Sclerosis Society is funding a new Phase 2 clinical trial to test the effectiveness of stem cell therapy on individuals with progressive forms of multiple sclerosis (MS), ... Read more

February 28, 2019February 28, 2019

Axim Improves Delivery of Cannabinoids in Chewing Gums

News

Axim Biotechnologies announced that it has succeeded in microencapsulating cannabinoids (chemical compounds in cannabis) into the company’s patented chewing gums, which are used to treat several disease symptoms, including ... Read more

February 26, 2019March 7, 2019

Cleveland Clinic Chosen for Phase 2 Trial Testing NurOwn Stem Cell Therapy in Progressive MS Patients

News

BrainStorm Cell Therapeutics announced the Cleveland Clinic is the first clinical site contracted in the United States for the Phase 2 multi-center study evaluating the company’s NurOwn mesenchymal stem cell (MSC) ... Read more

February 19, 2019February 22, 2019

Participants Sought for Clinical Trial Studying Effects of Lipoic Acid on Progressive MS

News

A clinical trial to test the effects of antioxidant treatment with lipoic acid on progressive forms of multiple sclerosis (MS) is recruiting 118 participants at seven sites in North America. ... Read more

February 14, 2019February 22, 2019

Continuous Use of Gilenya for Up to 3 Years Can Lead to 50% Drop in Annual Relapse Rates, Real-world Study Says

News

Multiple sclerosis patients who began treatment with Gilenya and stayed with it continuously showed a more than 50 percent reduction in annual relapse rates, a real-world study following these people ... Read more

February 13, 2019February 18, 2019

Almost 1 in 5 People Wrongly Diagnosed with MS at Two Specialized Centers in US, Study Finds

News

Almost one in five patients diagnosed with multiple sclerosis (MS) and referred to one of two MS-specialized centers in the U.S. were found to not have the disease, a ... Read more

January 29, 2019January 30, 2019

Funding Supports MS Research on Epigenetics and Fatigue in Australia

News

Australian researchers from the University of Newcastle and the Hunter Medical Research Institute (HMRI) have received funding for two projects that will study unexplored areas in multiple sclerosis (MS). The projects, ... Read more

January 7, 2019January 7, 2019

Biogen Starts Phase 3b Trial to Evaluate Tysabri Extended Interval Dosing in RRMS Patients

News

Biogen announced the start of a global Phase 3b clinical trial to evaluate the efficacy and safety of extended interval dosing (EID) with Tysabri (natalizumab) in patients with relapsing-remitting ... Read more

December 14, 2018December 14, 2018

MS Patients Report Beneficial Effects of Cannabis With Few Side Effects, Survey Shows

News

Many multiple sclerosis (MS) patients report that cannabis has beneficial effects on their symptoms with minimal side effects, according to a survey that also showed that varying effects on ... Read more

December 14, 2018December 14, 2018

Researchers Develop Smartphone-connected Device to Treat MS, Brain Disorders Remotely

News

Researchers at the Ural Federal University (UrFU) in Russia have developed a neuro-electrostimulation system that has the potential to treat different types of brain disorders, including multiple sclerosis (MS). ... Read more

December 11, 2018December 11, 2018

Glatect Added to Public Drug Plan in British Columbia as Sole RRMS Treatment of Its Type

News

Pendopharm’s Glatect (glatiramer acetate) — a treatment for patients with relapsing-remitting multiple sclerosis (RRMS) — has been added to the public drug plan in the Canadian province of British ... Read more

November 27, 2018November 29, 2018

Lifestyle Factors Tied to MS-related Depression, Large Study Finds

News

Changeable lifestyle factors influence the risk and severity of depression associated with multiple sclerosis (MS), a study based on a large group of patients shows. According to the study, alcohol ... Read more

November 8, 2018November 8, 2018

Pregnancy Briefly Lowers MS Relapse Rates and Treatment Reliance, Real-world Study Shows

News

Relapse rates in women with multiple sclerosis (MS) decline during pregnancy, as does the use of disease-modifying therapies, before both adjust to pre-pregnancy levels again, a large U.S. study ... Read more